Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1999-02-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.96.4.1609PMID 9990072PMCID PMC15534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Familial gastrointestinal stromal tumours with germline mutation of the KIT gene

  1998cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Long-range genomic rearrangements upstream of Kit dysregulate the developmental pattern of Kit expression in W57 and Wbanded mice and interfere with distinct steps in melanocyte development.

  1997cited by this paper
• c-kit mutation in a population of patients with mastocytosis.

  1997cited by this paper
• A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.

  1996cited by this paper
• Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase (*)

  1996cited by this paper
• Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line.

  1996cited by this paper
• Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.

  1996cited by this paper
• Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.

  1996cited by this paper
• Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

  1996cited by this paper
• Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

  1995cited by this paper
• Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.

  1995cited by this paper
• The mast cell and mast cell disease.

  1995cited by this paper
• Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.

  1995cited by this paper
• Protein modules and signalling networks

  1995cited by this paper
• The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis.

  1994cited by this paper
• Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation

  1994cited by this paper
• Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.

  1994cited by this paper
• Crystal structure of the tyrosine kinase domain of the human insulin receptor

  1994cited by this paper
• KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells.

  1993cited by this paper
• IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand.

  1993cited by this paper
• Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

  1993cited by this paper
• Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation.

  1992cited by this paper
• Loss of c-kit expression in cultured melanoma cells.

  1992cited by this paper
• c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.

  1992cited by this paper
• Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.

  1992cited by this paper
• TINEA VERSICOLOR: HISTOLOGIC AND ULTRASTRUCTURAL INVESTIGATION OF PIGMENTARY CHANGES

  1992cited by this paper
• Isolation, detection, and amplification of intact mRNA from dermatome strips, epidermal sheets, and sorted epidermal cells.

  1991cited by this paper
• The skin in mastocytosis.

  1991cited by this paper
• Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.

  1991cited by this paper
• Classification and diagnosis of mastocytosis: current status.

  1991cited by this paper
• The skin in mastocytosis.

  1991cited by this paper
• SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.

  1991cited by this paper
• Classification and diagnosis of mastocytosis: current status.

  1991cited by this paper
• The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

  1988cited by this paper
• Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus.

  1988cited by this paper
• The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

  1988cited by this paper
• The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene.

  1988cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper

• Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.

  2026cites this paper
• French guidelines for the management of nonadvanced mastocytosis in adults

  2025cites this paper
• Mastocitosis

  2025cites this paper
• TurboID-Based IRE1 Interactome Reveals Participants of the Endoplasmic Reticulum-Associated Protein Degradation Machinery in the Human Mast Cell Leukemia Cell Line HMC-1.2

  2024cites this paper
• Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why

  2024cites this paper
• Pharmaco‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G

  2024cites this paper
• Mastocytoses

  2024cites this paper
• Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases

  2024cites this paper
• An elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes: pathophysiological implications.

  2023cites this paper
• Extrinsic and intrinsic modulators of anaphylaxis.

  2023cites this paper
• Mastocytosis and Skin Cancer: The Current State of Knowledge

  2023cites this paper
• Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management

  2023cites this paper
• Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia

  2023cites this paper
• Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation

  2022cites this paper
• Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

  2022cites this paper
• Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.

  2022cites this paper
• Selective immunocapture reveals neoplastic human mast cells secrete distinct microvesicle‐ and exosome‐like populations of KIT‐containing extracellular vesicles

  2022cites this paper
• KIT D816V is dimerization‐independent and activates downstream pathways frequently perturbed in mastocytosis

  2022cites this paper
• Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently

  2021cites this paper
• Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021

  2021cites this paper
• PATHOGENIC AND DIAGNOSTIC RELEVANCE OF KIT IN PRIMARY MAST CELL ACTIVATION DISORDERS.

  2021cites this paper
• Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms.

  2021cites this paper
• Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised lymphadenopathy and osteosclerosis

  2021cites this paper
• Mast Cell Activation Disorders

  2021influential citation
• FIGURE 1: OVERVIEW OF DIAGNOSTIC STEPS FOR ADULTS WITH MASTOCYTOSIS

  2021cites this paper
• MRGPRX2 Signaling in Mast Cells and Mastocytosis (Urticaria Pigmentosa)

  2021influential citation
• The association of Greig syndrome and mastocytosis reveals the involvement of hedgehog pathway in advanced mastocytosis.

  2021cites this paper
• Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

  2021cites this paper
• The Role of Avapritinib for the Treatment of Systemic Mastocytosis

  2021cites this paper
• c-Kit - The Novel Receptor: Physiological Roles, Downstream Signaling and Implications in Cancer

  2021cites this paper
• Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management

  2021cites this paper
• Is BCL11B a potential candidate gene for the diffuse cutaneous mastocytosis: A case report

  2020cites this paper
• Die Wirkung des Tyrosinkinase-Inhibitors Crenolanib auf autoaktive Isoformen der Rezeptortyrosinkinase KIT

  2020influential citation
• Comprehensively analyze the expression and prognostic role for ten-eleven translocations (TETs) in acute myeloid leukemia

  2020cites this paper
• Criteria for the regression of pediatric mastocytosis: a long-term follow-up.

  2020cites this paper
• Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis

  2020cites this paper
• Cutaneous mastocytosis mimicking hypertrophic scars: A case report

  2020cites this paper
• Mast Cell and Basophil Cell Lines: A Compendium.

  2020cites this paper
• Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild‐type KIT patients

  2020cites this paper
• Exon 8 KIT mutation and pulmonary eosinophilia

  2020cites this paper
• KIT‐related piebaldism in a Chinese girl

  2020cites this paper
• Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells.

  2020cites this paper
• Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes

  2020cites this paper
• Inherited and Acquired Hyperpigmentation

  2019cites this paper
• Raccomandazioni sull'uso della triptasi nella diagnosi dell'anafilassi e della mastocitosi

  2019cites this paper
• Recent advances in the understanding and therapeutic management of mastocytosis

  2019cites this paper
• Recommendations for the use of tryptase in the diagnosis of anaphylaxis and mastocytosis

  2019cites this paper
• A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers

  2019cites this paper
• KIT ligand protects against both light-induced and genetic photoreceptor degeneration

  2019cites this paper
• KIT and Other Mutations in Mastocytosis

  2019cites this paper
• Comparison of lesional skin c‐KIT mutations with clinical phenotype in patients with mastocytosis

  2018cites this paper
• KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog)

  2018cites this paper
• A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice.

  2018cites this paper
• Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management

  2018cites this paper
• Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis using the novel application of autoMACS magnetic separation and flow cytometry.

  2018cites this paper
• Kit Mutations: New Insights and Diagnostic Value.

  2018cites this paper
• Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis.

  2018cites this paper
• Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

  2018cites this paper
• Impact of somatic and germline mutations on the outcome of systemic mastocytosis.

  2018cites this paper
• Bone Marrow Expression of Mast Cell Disorders.

  2018cites this paper
• R634W KIT Mutation in an Adult With Systemic Mastocytosis

  2017cites this paper
• Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing

  2017cites this paper
• Targeted Treatment Options in Mastocytosis

  2017cites this paper
• Pathogenesis and Pathology of Mastocytosis.

  2017cites this paper
• Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

  2017cites this paper
• Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine.

  2017cites this paper
• Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.

  2017cites this paper
• The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm

  2017cites this paper
• Mastocytosis in Children

  2017cites this paper
• Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report

  2017cites this paper
• Clinical features of mastocytosis at pediatric patients

  2017cites this paper
• What is New in Gastrointestinal Stromal Tumor?

  2017cites this paper
• CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

  2017cites this paper
• Regulation of mast cell function and survival in health and disease

  2016cites this paper
• Current approach to cutaneous mastocytosis in childhood.

  2016cites this paper
• Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management

  2016cites this paper
• Identification of Bromodomain-Containing Protein 4 (BRD4) as a Novel Marker and Epigenetic Target in Systemic Mastocytosis and Mast Cell Leukemia

  2016cites this paper
• Gastrointestinal manifestations of systemic mastocytosis

  2016cites this paper
• Update on Mastocytosis (Part 1): Pathophysiology, Clinical Features, and Diagnosis.

  2016cites this paper
• An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer

  2016cites this paper
• Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.

  2016cites this paper
• CME Information

  2016cites this paper
• To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation.

  2016cites this paper
• Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis

  2016cites this paper
• Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

  2016cites this paper
• Update on Mastocytosis (Part 1): Pathophysiology, Clinical Features, and Diagnosis.

  2016cites this paper
• The genetic basis of mast cell activation disease - looking through a glass darkly.

  2015cites this paper
• Review papers The role of KIT gene mutations in pathogenesis of pediatric mastocytosis

  2015cites this paper
• Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

  2015cites this paper
• Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.

  2015cites this paper
• Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation.

  2015cites this paper
• Antiproliferating Activity of Esculetin on Acute Myeloid Leukemic Cell Line Potential Role in Therapy

  2015cites this paper
• Impaired function of bone marrow stromal cells in systemic mastocytosis.

  2015cites this paper
• In vivo model for mastocytosis: A comparative review.

  2015cites this paper
• Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable

  2015cites this paper
• Esculetin Downregulates the Expression of AML1-ETO and C-Kit in Kasumi-1 Cell Line by Decreasing Half-Life of mRNA

  2015cites this paper
• Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder

  2015cites this paper
• Update on recurrent genetic aberrations in acute myeloid leukemia

  2015cites this paper
• Cutaneous and Systemic Mastocytosis in Children: A Risk Factor for Anaphylaxis?

  2015cites this paper
• Paediatric mastocytosis: a systematic review of 1747 cases

  2015cites this paper